Analyst Reco. aTyr Pharma, Inc. Deutsche Boerse AG

Equities

471A

US0021202025

Real-time Estimate Tradegate Other stock markets 04:43:32 2024-06-13 EDT			5-day change	1st Jan Change
1.755 ^EUR	-1.40%		+4.88%	+33.33%

06-05	ATyr Pharma, Inc. will Change its Ticker to ATYR. from LIFE	CI
05-14	ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier	03-15	MT
Piper Sandler Adjusts Price Target on aTyr Pharma to $20 From $13, Maintains Overweight Rating	23-07-21	MT
Oppenheimer Downgrades aTyr Pharma to Perform From Outperform, Removes $17 Price Target	23-07-05	MT
Piper Sandler Adjusts Price Target on aTyr Pharma to $13 From $9, Keeps Overweight Rating	23-04-11	MT
Roth MKM Reinstates aTyr Pharma at Buy With $9 Price Target	23-03-06	MT
RBC Cuts Price Target on aTyr Pharma to $19 From $20, Maintains Outperform, Speculative Risk	23-03-02	MT
Oppenheimer Adjusts aTyr Pharma Price Target to $25 From $21, Maintains Outperform Rating	22-08-16	MT
Piper Sandler Adjusts Price Target on aTyr Pharma to $14 From $11, Reiterates Overweight Rating	22-08-16	MT
HC Wainwright Adjusts Price Target on aTyr Pharma to $35 From $11, Reiterates Buy Rating	22-07-21	MT
Piper Sandler Adjusts ATyr Pharma's Price Target to $11 From $19, Reiterates Overweight Rating	22-05-18	MT
RBC Cuts Price Target on ATyr Pharma to $20 From $22, Maintains Outperform-Speculative Risk Rating	22-05-10	MT
HC Wainwright Adjusts aTyr Pharma's Price Target to $11 from $18, Keeps Buy Rating	21-11-11	MT
ATYR PHARMA : RBC Initiates aTyr Pharma at Outperform, Speculative Risk, Sets Price Target at $22, Says Lead Product is Underappreciated	21-10-12	MT
ATYR PHARMA : Piper Sandler Starts aTyr Pharma at Overweight With $19 Price Target	21-09-21	MT
ATYR PHARMA : Roth Capital Adjusts aTyr Pharma's Price Target to $21 from $20, Keeps Buy Rating	21-09-14	MT
ATYR PHARMA : Oppenheimer Adjusts aTyr Pharma PT to $20 From $14 as ATYR1923 Pulmonary Sarcoidosis Results Surpass Expectations, Maintains Outperform Rating	21-09-14	MT
ATYR PHARMA : Jones Trading Adjusts Price Target for aTyr Pharma to $20 From $15, Maintains Buy Rating	21-09-13	MT
ATYR PHARMA : HC Wainwright Adjusts aTyr Pharma PT to $18 From $13, Maintains Buy Rating	21-09-13	MT
ATYR PHARMA : JonesTrading Initiates Coverage on ATyr Pharma With Buy Rating, $15 Price Target	21-05-18	MT
ATYR PHARMA : Laidlaw Starts ATyr Pharma at Buy With $18 Price Target	21-05-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. aTyr Pharma, Inc. Deutsche Boerse AG

Equities

471A

US0021202025

Analyst Reco.

Filters